Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain
tumor. Patients with GBM often have poor prognoses, with a median survival of∼ 15 months …

Cells and their derived extracellular vesicles (EVs) or exosomes contain unique molecular
signatures that could be used as biomarkers for the detection of severe diseases such as …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Background New precision medicine therapies are urgently required for glioblastoma
(GBM). However, to date, efforts to subtype patients based on molecular profiles have failed …

Glioblastoma multiforme (GBM) is one of the worst brain tumors arising from glial cells,
causing many deaths annually. Surgery, chemotherapy, radiotherapy and immunotherapy …

Though surgical biopsies provide direct access to tissue for genomic characterization of
brain cancer, they are invasive and pose significant clinical risks. Brain cancer management …

Objective Summarize evidence for use of advanced MRI techniques as monitoring
biomarkers in the clinic, and highlight the latest bench-to-bedside developments. Methods …

Glioblastoma multiforme (GBM) is a lethal disease characterized by an overall survival of
about 1 year, making it one of the most aggressive tumours, with very limited therapeutic …

Genome-wide fragmentation patterns in cell-free DNA (cfDNA) in plasma are strongly
influenced by cellular origin due to variation in chromatin accessibility across cell types …